Skip to main content

Forte Biosciences, Inc.

FBRXDelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001419041

Forte Biosciences, Inc. was delisted in 2026; its insiders filed their last Form 4 on Aug 27, 2026; 86 institutions reported holding it in 13F filings for Q2 2026, worth $432.7M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Forte Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Forte Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Forte Biosciences, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Kornfeld StevenDirector0Aug 27, 20262
Brun Scott C.Director–Aug 27, 20262
Gryska David WDirector0Aug 27, 20262
Vincent Richard GDirector–Aug 27, 20262
Finck Barbara KDirector–Aug 27, 20261
Kapoor Shivpreet SinghDirector–Aug 27, 20262
Doberstein Stephen KDirector–Aug 27, 20262
Riley Antony ACHIEF FINANCIAL OFFICER0Aug 27, 20267
Wagner Paul A.SEE REMARKS0Aug 27, 20267
Williams Donald AllenDirector59,405Aug 22, 20240
Eichenfield LawrenceDirector–Aug 22, 20240
Chen Hubert CSee remarks93,405Jan 3, 20240
Walker Patricia SDirector–Jun 2, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 2, 2026 (view filing)Dec 30, 20253 daysRiley Antony ACHIEF FINANCIAL OFFICERPPurchase+9.68K$26.33+$254.9K+30.4%41.5K after
Nov 22, 2024 (view filing)Nov 211 dayRiley Antony ACHIEF FINANCIAL OFFICERPPurchase+22.5K$5.55+$125.0K+272.5%30.8K after
Dec 20, 2023 (view filing)Dec 182 daysWagner Paul A.See RemarksPPurchase+10.0K$0.75+$7.50K+0.6%1.82M after
Dec 15, 2023 (view filing)Dec 13-142 daysWagner Paul A.See RemarksPPurchase+20.5K$0.7097+$14.6K+1.1%1.81M after2 lots
Dec 12, 2023 (view filing)Dec 11-121 dayWagner Paul A.See RemarksPPurchase+29.8K$0.65+$19.4K+1.7%1.79M after2 lots
Dec 8, 2023 (view filing)Dec 7-81 dayWagner Paul A.See RemarksPPurchase+51.2K$0.5917+$30.3K+3.0%1.76M after2 lots
Nov 22, 2023 (view filing)5:51 PM ETNov 20-222 daysWagner Paul A.See RemarksPPurchase+7.37K$0.4371+$3.22K+0.4%1.71M after4 lots
Dec 19, 2022 (view filing)Dec 15-164 daysWagner Paul A.See RemarksPPurchase+100.0K$1.05+$104.8K+7.8%1.38M after2 lots
Sep 8, 2021 (view filing)Sep 71 dayWagner Paul A.See RemarksSSale−1.00M$4.35−$4.35M−43.9%1.28M after
Sep 7, 2021 (view filing)Sep 7Same dayRiley Antony AChief Financial OfficerSSale−25.0K$4.24−$106.1K−69.3%11.1K after2 lots